P3.13-22 Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer

Authors :: Hideo Yasugahira
Takeshi Morimoto
Toshihiro Shiratori
Yoshiko Ishioka
Hiroshi Tanaka
Koichi Okudera
Yoshinori Hasegawa
Shingo Takanashi
Masamichi Itoga
Hideyuki Nakagawa
Keisuke Baba
Yoshihito Tanaka
Sadatomo Tasaka
Kageaki Taima
Source :: Journal of Thoracic Oncology. 13:S984
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Pulmonary and Respiratory Medicine
business.industry
First line
Afatinib
Mutant
medicine.disease
Oncology
medicine
Cancer research
Re challenge
Non small cell
Lung cancer
business
medicine.drug

Full Text Access

Tools